We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Below-Knee Stent Trial Approved

By HospiMedica staff writers
Posted on 07 Jul 2006
A clinical trial will investigate the use of minimally invasive stent placement to treat severe peripheral arterial disease (PAD) below the knee

The study will be the first in the United States to evaluate the Xpert expandable nitinol stent in the blood vessels below the knee. More...
The stent is manufactured by Abbott Vascular (Abbott Park, Il, USA) and is currently cleared in the United States for treating blockages in the biliary ducts that carry digestive enzymes from the liver. The self-expanding stent is a tiny cylinder made of metal mesh that is guided into place by a catheter through the blood vessels to the site of the blockage under x-ray guidance. The stent is deployed through the catheter and expanded to prop open the diseased artery.

"The Xpert stent is particularly appropriate for this trial because it is the only self-expanding stent that comes in a variety of sizes small enough to treat the blood vessels below the knee,” said principal investigator Dr. James Joye of El Camino Hospital (Mountain View, CA, USA), which will be among the sites participating in the study. The study is also important because it is one of only a very few independent, physician-sponsored efforts.”

The trial is sponsored by VIVA Physicians Inc. (VPI, Rosemont, IL, USA), a multi-disciplinary group of independent doctors who are nationally known experts in the diagnosis and management of peripheral vascular diseases and who have joined together to advance education in vascular medicine and support research and innovative treatment options. VPI set the protocol, applied for the investigational device exemption (IDE), and is responsible for data collection, evaluation, and reporting of the Xpert stent study, called XCELL.



Related Links:
Abbott Vascular

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.